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Abstract
Background: Breast Implant Illness (BII) is a term used to describe a variety of symptoms by patients with breast implants
for which there are no abnormal physical or laboratory findings to explain their symptoms. There currently exists a difference of opinion among clinicians and patients concerning the diagnosis and treatment of patients self-reporting BII.
Objectives: The first aim of this study was to determine if there is a valid indication for “en bloc” capsulectomy in patients
self-reporting BII and if the type of capsulectomy performed alters long-term symptom improvement. The second goal
was to identify any clinical laboratory differences between the cohorts. This study was funded by the Aesthetic Surgery
Education and Research Foundation (ASERF).
Methods: A prospective blinded study enrolled 150 consecutive subjects divided equally into 3 cohorts: (A) women with
systemic symptoms they attribute to their implants who requested implant removal; (B) women with breast implants requesting removal or exchange who do not have symptoms they attribute to their implants; and (C) women undergoing
cosmetic mastopexy who have never had any implanted medical device. The subject’s baseline demographic data and a
systemic symptoms survey, including PROMIS validated questionnaires, was obtained before surgery and at 3-6 weeks,
6 months, and 1 year. Blood was collected from all 3 cohorts and implant capsules were collected from Cohorts A and B.
Results: 150 patients were enrolled between 2019-2021. Follow-up at 3-6 weeks for all 3 cohorts was between 98%-100%,
78%-98% at 6-months, and 1 year data is currently at 80%. The type of capsulectomy; intact total, total, or partial all showed
similar symptom improvement with no statistical difference in the reduction of symptoms based on the type of capsulectomy.
Conclusions: This study addresses one of the most discussed questions by plastic surgeons, patients, their advocates,
and social media. The findings show that patients who self-report BII demonstrate a statistically significant improvement
in their symptoms after explantation and that this improvement persists for at least 6 months. This improvement in selfreported systemic symptoms was seen regardless of the type of capsulectomy performed.
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Level of Evidence: 2  

Possible associations between systemic illness and breast
implants have been hypothesized for over half a century.
Initial reports of “Human Adjuvant Disease” appeared in
the literature based upon complications associated with
the injection of paraffin, processed petroleum, and adulterated liquid silicone either directly into the breasts or
the use of early generation silicone filled elastomer implants.1,2 Shoenfeld first coined the term ASIA Syndrome
(Autoimmune Syndrome Induced by Adjuvants) in 2011.3
This syndrome continues to be discussed in the world literature though most publications are opinions, anecdotal
reports, retrospective chart reviews, or editorials. ASIA remains a syndrome without a distinct causative agent and
no clear temporal association, often with decades between initial exposure and the onset of multiple nebulous
symptoms.
Over the last decade the term Breast Implant Illness
has gained traction on social media platforms. In the medical literature it refers to a variety of systemic symptoms
reported by women with breast implants for which there
are no abnormal physical findings or laboratory evaluations to explain their symptoms.4 There is also no specific constellation of symptoms and no diagnostic criteria,
and therefore it is functionally a diagnosis of exclusion.5
Previous reports have shown that some patients experience symptom improvement after implant removal.6 After
other plausible causes for the patient’s systemic symptoms, treatment options most often include removal of the
patient’s breast implants.7 The Breast Implant Illness social
media groups and some surgeons hypothesize that not
only does the implant need to be removed but also the surrounding capsular tissue “en bloc” for symptom improvement.8 They also believe that toxins from the implant are
responsible for the symptoms are also present in the capsule, and therefore failure to entirely remove, even leaving
even a small portion of the capsule during explantation,
leaves these toxins behind and precludes symptom improvement. Social media posts often point to studies that
suggest possible toxins such as silicone and heavy metals,
and voice concerns about bacteria and fungi in or around
the implants.5
The definition of an “en bloc” capsulectomy, as used in
BII social media groups, refers to implant removal where
the implant capsule remains completely intact around the
implant and the implant and capsule are removed together

as 1 unit.9 The term “en bloc” has inappropriately been
overextended far from its original surgical definition.10
“En bloc” is incorrectly used when referring to procedures other than the treatment of malignancy where a clear
margin is required for cure.11 Described in 1894, Halsted’s
“en bloc” resection for the treatment of breast cancer included the resection of the entire breast including the
pectoralis major, minor, and axillary lymph nodes in a
“single swath of tissue”.12 In the plastic surgery literature,
“en bloc” capsulectomy is defined as the complete removal of the breast implant contained within the capsule
along with a contiguous layer of healthy tissue.10 For breast
implant removal, the only scientifically proven indication for
“en bloc” capsulectomy is the treatment of Breast Implant
Associated Anaplastic Large Cell Lymphoma, (ALCL), a
T-cell lymphoma, or other malignancies of the capsule.2 It
can be surgically preferable to remove a ruptured gel implant while still inside the capsule to contain any gel from
potentially leaking outside of the implant shell or capsule.
In the case of capsular contracture, there is currently no
scientifically proven benefit of removing an implant in the
capsule, or removing a thin, asymptomatic capsule in a
patient for a benign condition.2 Total capsulectomy also
carries higher surgical risks, including hematoma, contour irregularities, and pneumothorax if the implant is in a
subpectoral position, and often requires a larger incision
and more operative time with the inherent risks involved.2
There are potential aesthetic complications as well, particularly when the implant lies in the sub-glandular plane
under very thinned soft tissue coverage or was previously
placed through a peri-areolar incision (Figure 1).
There currently exists a state of clinical equipoise with
no consensus among the clinical community, patient advocates, or the FDA regarding the care of women who
self-report BII. All concerned stakeholders have expressed
the desire to collect both real world evidence of systemic
symptoms as well as valid scientific evidence based on
biospecimen analyses. As surgeons we are tasked with
balancing the psychological and aesthetic gains of breast
implant surgery against potential health risks.13 This study
aims to reconcile the clinical equipoise and better inform
clinicians, patients, and regulators. Previously published
papers on symptom improvement after implant removal
are retrospective, have no control cohort, or have no long
term follow up.14,15 The purpose of this study is to address
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Figure 1. (A) A 56-year-old female patient desires explantation for self-reported BII, underwent total capsulectomy through
IMF incision and the (B) resulting soft-tissue deformity with previous periareolar incision and thin capsules in subglandular
placement. (C) A 45-year-old female patient desires explantation for self-reported BII, underwent intact total capsulectomy. (D)
Resulting deformity with previous submuscular placement.

the potential etiologies that have previously been hypothesized to be associated with the development of BII.16
These include heavy metals, microbes, microbial toxins,
cytokines, alternate causation (vitamin D deficiency, thyroid issues, heavy metals from previous tattoos or diet,
and preexisting anxiety or depression or connective tissue
disease [CTD]). The second goal of this study is to determine who will benefit from explantation of their breast implant and whether the type of capsulectomy – total, partial,
or “en bloc” makes any difference on systemic symptom
improvement and are there any baseline data points that
may predict which patients may have reduced symptoms,
to what extent, and for how long. The third goal of the
study aims to evaluate if there is any evidence of a dose response based on number of years a patient was implanted
or whether the implant fill – saline vs silicone, implant shell
– texture vs smooth, or position of the device- subglandular
vs submuscular has significance. Additionally, all explanted capsule tissue were photographed and analyzed

to explore any potential statistical differences between the
capsule pathology, microbe diversity, heavy metal content,
and immunological differences between the cohorts.

METHODS
A prospective, controlled study was designed to evaluate
breast implant capsules, peripheral blood, baseline demographics, baseline patient reported systemic symptoms,
and PROMIS questionnaires. The study was registered
on ClinicalTrials.gov (NCT04255810) and was entirely
funded by the Aesthetic Surgery Education and Research
Foundation (ASERF). All patients signed an informed
consent for the use of their de-identified biospecimens
and surveys and the study followed the guidelines of
Declaration of Helsinki and was approved by the Rhode
Island Hospital Institutional Review Board (Providence, RI).
The first patient was enrolled in November 2019 and the
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Table 1. Inclusion and Exclusion Criteria
Inclusion Criteria
a) Genetic female

c) Agrees to donate biospecimens
to the research study which may
not be returned to the subjects

d) Age 30-65

a) Has any breast disease considered
to be pre-malignant in 1 or both
breasts, a history of breast cancer, or
an untreated cancer of any type

f) HIV positive (based on medical history)

b) Subject lives more than 3 hours
travel from the treating surgeon

g) Has been diagnosed with BIA-ALCL

c) Has an abscess or infection

h) Has any medical condition such as obesity (BMI >
40), diabetes, chronic lung or severe cardiovascular
disease that might result in unduly high surgical
risk, and/or significant postoperative complications

d) Is pregnant or nursing or has had a
full-term pregnancy or lactated within
3 months of enrollment

i) Has been implanted with any device that has not
been approved by the FDA or equivalent regulatory
agency outside the US

e) Has been implanted with any implantable medical device or silicone
implant other than breast implants
(except intraocular lenses)

j) Works for any breast implant manufacturer or any
of their subsidiaries, the study surgeon, or are directly related to anyone that works for a breast implant manufacturer or any of their subsidiaries

study was fully enrolled in May 2021. Patients were consecutively enrolled into 1 of 3 cohorts: (A) 50 women with
implants and symptoms self-defined as BII; (B) 50 women
with implants undergoing either an implant replacement
or explantation without symptoms they attributed to their
implants; and (C) 50 women undergoing an elective aesthetic mastopexy who had no previous exposure to any
implanted device. Strict inclusion criteria required patients
live within 3 hours of an investigator and have no systemic
evidence of active infection or untreated malignancy and
be between 30-65 years of age. Patients with any current
or previous diagnosis of BIA-ALCL, HIV, breast cancer,
and genetic males were excluded (Table 1). Five surgeon
collaborators agreed to enroll patients, follow their enrolled subjects for a period of 1 year, and comply with a
strict study protocol. The patients completed a systemic
symptoms questionnaire in person, on paper at baseline,
3-6 weeks, 6-months, and 1 year post-operatively and patient surveys were de-identified and assigned a site and
subject number prior to data review. This included details
about allergies, menopausal status, medications, presence
of dental amalgams, 22 systemic symptoms, presence of
autoimmune disease, other medical issues, physicians
they have seen for their symptoms, personal or family history of autoimmune disease, any significant life changes,
their primary source of medical information, the type of
implant (brand, fill, surface), when the implant was placed,
and any previous implants. (Appendix A, available online
at www.aestheticsurgeryjournal.com) Patients also completed National Institutes of Health (NIH) Patient Reported
Outcomes Measurement Information System (PROMIS)

questionnaires. These are a standardized set of patientreported outcomes that cover physical, mental, and social
health. PROMIS measures generate a T-score with a mean
of 50 and standard deviation of 10 in a reference population (usually U.S. general population). The specific questionnaires used included Cognitive Function, Fibromyalgia,
Fatigue and Anxiety/Depression. Case Report Forms (CRF)
documented patient demographics including age, marital
status, educational level, race, ethnicity, reproductive history, history of breast feeding and any history of mastitis,
medical history, medications, tobacco or marijuana use,
history of anxiety/depression, autoimmune illness, and
presence of tattoos, their color, and percent body surface.
Data accumulated from the completed PROMIS questionnaires and surveys were analyzed and reviewed by a clinical psychologist with expertise in anxiety.
Investigator surgeons completed a detailed Surgeon
Observation Form on the day of surgery documenting
style of implant, manufacturer, fill, shell, pocket location,
description of capsule, any evidence of rupture, deflation,
or double capsules, type of capsulectomy performed, and
photographs of implant and capsules were required on all
explants. All patients in Cohort A and B had at least a partial
capsulectomy. For the purposes of this study, we divided
capsulectomy into 3 types: Total intact capsulectomy- the
implant was removed in the capsule with the capsule completely intact (Figure 2 and Appendix B, available online at
www.aestheticsurgeryjournal.com). This is what has been
described by social media as “en bloc”. Total capsulectomythe entire capsule was removed whether with the implant
in the capsule but the capsule not completely intact, or the
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implant was removed prior to total capsule removal, and
partial capsulectomy- some capsule was left behind in the
implant pocket. There were no patients who had the entire
capsule left as some capsule tissue (more than a small biopsy) was removed for the multiple study specimens in all
patients.
Biospecimens obtained the day of surgery included
systemic blood in all 3 cohorts and capsule tissue in
Cohorts A and B. Blood and capsule tissue were collected, de-identified, blinded with respect to cohort, and
sent to Brown University within 24 hours of collection.
Approximately 10 grams of capsule tissue was removed
from each capsule, right and left sides, and sent to Eurofins
Frontier Global Sciences, LLC. (Tacoma, WA), an advanced
analytical laboratory specializing in heavy metals analysis.
Under sterile conditions, swabs were obtained from the
surface of the implant and capsule and sent along with a
piece of capsular tissue to MicroGenDx (Lubbock, TX) for
PCR/Next Generation Sequencing (NGS) providing a rigorous evaluation of exposure to microbes.
The remainder of the capsule tissue and blood were
sent to Brown University Department of Pathology where
capsule hematoxylin and eosin (H&E) histopathology was
performed. Blood was tested for C-reactive Protein (CRP),
thyroid levels, vitamin D level, and complete leukocyte
count with differential. Within 24 hours of collection the
sera were stored in 2 mL aliquots at -80C until use. One aliquot was analyzed with a BD Biosciences LSRII Analyzer/
Flow Cytometer for cytokines IL-2, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-13, IL-17A, IL17F, IL-22, IFNγ, and tumor necrosis factor α
(TNFα) with the LEGENDplex Human T-helper (Th) Cytokine
Panel (13-plex) (Cat No 741001; BioLegend, San Diego, CA).
Each analysis was controlled by an internal standard provided by the manufacturer. Prior to analysis all serum samples were diluted 1:10 to reduce background interference

and analyzed in duplicate, while a subset of samples was
also analyzed undiluted (neat). The remaining portion of
the patient’s serum was further analyzed at the Johns
Hopkins University Department of Medicine, Dermatology,
Allergy, and Clinical Immunology (DACI) Reference
Laboratory for antibodies specific for bacterial enterotoxin
superantigens as these superantigens that have been potentially linked to a range of immune dysfunctions.17-19 Sera
from the 3 Cohorts were analyzed by the ImmunoCAP
250 System (Thermofisher Scientific, Kalamazoo, MI) for
the presence and levels of IgE and IgG antibodies specific
for superantigens SSA, SSB and TSST Staphylococcal enterotoxins. Antibody levels above the analytical sensitivity
of the assays (IgE assay: 0.1 kUa/L where 1 IU = 2.4 ng of
IgE; IgG assay; 2 mga/L where the “a” in the unit refers to
“allergen-specific”) were defined as positive and an indication of enterotoxin superantigen exposure.

Statistical Analysis
Pairs of cohorts were compared at baseline using logistic
regression analyses with cohort as the dependent variable and baseline characteristic as the explanatory variable. Additionally, age and BMI were compared between
pairs of cohorts using a 2-sided 2-sample t test. Follow-up
symptom resolution at 3-6 weeks and 6 months were compared across 3 cohorts, and within Cohort A and Cohort
B by method of explantation (partial, total, en bloc), using
Fisher’s exact test for categorical variables and analysis of
variance for percent reduction in number of symptoms.
Only patients who had the given symptom at baseline
were included in the analysis. For the PROMIS data, the
PROMIS Normative Score, moderate to severe, is defined
as a value greater then, or equal to sixty. Comparisons
were also made between pairs of cohorts using Fisher’s
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Figure 2. (A) A total intact capsulectomy, (B) total capsulectomy, and (C) partial capsulectomy.
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Table 2. Baseline Demographics
Cohort B

Cohort C

30-65 (mean 44.5)

30-65 (mean 46.9)

30-63 (mean 46.5)

Menopausal status

Pre-menopausal: 62%
Peri-menopausal: 14%
Post-menopausal: 24%

Pre-menopausal: 56%
Peri-menopausal: 22%
Post-menopausal: 22%

Pre-menopausal: 62%
Peri-menopausal: 14%
Post-menopausal: 24%

BMI

17.9-25.5 (median 26.2)

17.5-31 (median 22.4)

19-34 (median 24.9)

Saline: 64%
Gel: 36%
Smooth: 90%
Textured: 10%

Saline: 22%
Gel: 78%
Smooth: 23%
Textured: 77%

Medicines: 48%
Pollen: 50%
Dust: 40%
Gluten: 14%

Medicines: 36%
Pollen: 52%
Dust: 30%
Gluten: 2%

Medicines: 28%
Pollen: 26%
Dust:14%
Gluten: 0%

26%

16%

14%

High School/GED: 6%
Some college/vocational school: 32%
College Graduate: 42%
Post-graduate education: 20%

High School/GED: 4%
Some college/vocational school: 26%
College Graduate: 46%
Post-graduate education: 24%

High School/GED: 13%
Some college/vocational school: 9%
College Graduate: 55%
Post-graduate education: 23%

Age

Implant type

Allergies

Marijuana smoker- former and current
Education Level

exact test for categorical variables and a two-sided 2
sample t-test for percent reduction in number of symptoms. A P-value of ≤0.05 was statistically significant.

RESULTS
Follow-up at the time of data lock was 98%-100% at 3-6
weeks and 78%-98% at 6 months for all 3 cohorts.

Demographics
There was no statistical difference between Cohort A, B
and C with respect to age, marital status, educational level,
cigarette smoking, or a history of lactation problems. The
age range in Cohort A was 30-65 with a mean of 44.5, the
age range in Cohort B was 30-65 with a mean of 46.9, and
the age range in Cohort C was 30-63 with a mean of 46.5.
There was no statistical difference in medication use except cohort A used a statistically higher amount of Aspirin/
NSAIDs, prescription pain medications, and other herbal/
nonprescription medicines than the other 2 cohorts. Cohort
A also reported significantly more marijuana use, more tattoos, and more allergies, including allergies to medicines,
pollen, mold, gluten, dust, and wheat. The BMI was higher
in Cohorts A and C as compared to B. Patients were asked
at baseline what was their primary source of medical information. Social media was the primary source of medical
information for 58% of patients in Cohort A, 3% of patients
in Cohort B, and 2% in Cohort C (Table 2 and Appendix C,
available online at www.aestheticsurgeryjournal.com).

Medical History
There was a statistically significant increased incidence of
self-reported illness in Cohort A as compared to the other 2
cohorts with respect to Fibromyalgia, Chronic Fatigue, anxiety/depression, ANA positive, Sjogren’s Syndrome, irritable
bowel syndrome, rheumatological/autoimmune disease,
and rheumatoid arthritis. There was no statistical difference
between Cohorts A, B and C with respect to self-reported
history of osteoarthritis, thyroid disease, Hashimoto’s thyroiditis, rheumatoid arthritis, presence of Rheumatoid factor,
and the presence of rheumatologic/autoimmune disease or
family history of rheumatologic diseases.

Implant Characteristics
Cohort A
Sixty-four percent of implants in this cohort were saline and
90% had a smooth surface. Seventy-eight percent of implants were placed for primary augmentation and 22% were
placed for revision augmentation. Implants were placed
been 1989 and 2019 with a mean of twelve years at the
time of removal. Eighty-eight percent of implants were intact, 4% had gel bleed, 4% ruptured gel, 4% deflated saline.
Capsules were described as Grade 1 in 78%, Grade 2 in 8%,
Grade 3 in 12%, Grade 4 in 2%. of patients. Seventy-two percent of capsules were described as thin and transparent.

Cohort B
Seventy-eight percent of implants in this cohort were silicone gel and 57% were textured. Seventy-four percent of
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Symptoms
Over 100 symptoms have been reported by women with
self-described breast implant illness with no specific constellation of symptoms.2 The systemic symptom survey
asked about the twenty-two most frequently reported
symptoms and patients could write in additional symptoms. The most common symptoms reported by the Cohort
A patients were fatigue (96%), brain fog (90%), joint pain
(82%), muscle pain/weakness (80%), headaches (78%), low
libido (78%), dry eyes (76%), memory issues (76%), anxiety
(72%), and hair loss (66%), which are consistent with other
reports on patients with self-reported BII. Cohorts B and
C experienced significantly fewer symptoms than Cohort
A with no statistically significant difference in symptoms
reported between Cohort B and Cohort C, at baseline. As
compared to Cohorts B and C, Cohort A reported a statistically higher incidence of headaches, low libido, abdominal pain, hair loss, dry eyes, fatigue, weight gain, memory
issues, rash, heartburn, diarrhea, dry mouth, anxiety, cold
intolerance, weight loss, depression, brain fog, joint pain,
irregular heartbeat, insomnia, muscles pain/weakness, and
numbness/tingling in extremities. The average number of
baseline symptoms in Cohort A was 13.4 (range 3-22), for
Cohort B 2.4 (range 0-13), and for Cohort C 1.4 (range 0-7).
In Cohort B 30% reported no symptoms, the most common
symptoms reported in this group were fatigue (26%) and
headache (26%). Fifty percent of Cohort C reported no
symptoms at baseline, the most common symptoms reported were headache (20%) and anxiety (18%). Two patients in Cohort A were diagnosed with other diseases
during the study follow up period, 1 patient who did not
achieve symptom relief was diagnosed with a brain tumor
1 year post operatively, the second patient was diagnosed
with multiple myeloma 6 months post operatively and is
undergoing treatment.

PROMIS Data
The PROMIS baseline data showed a statistically higher
level of fatigue, anxiety, and sleep disturbance in Cohort
A as compared to the other 2 cohorts. Cohort A’s anxiety,

fatigue, and sleep disturbance improve from baseline to
3-6 weeks and their scores for anxiety and fatigue were
stable through 6-month follow-up but remained higher
at all time points than the other 2 cohorts. At 3-6 weeks,
78% of Cohort A approached normalized scores for the
PROMIS anxiety value (from the severe or moderate range
to mild or none) which increased to 86% of patients in
Cohort A demonstrating the same at 6 months. Fatigue
normalized in 85% of Cohort A at 3-6 weeks and was
normalized in 79% of the Cohort at 6 months. Eighty-three
percent of Cohort A had normalized sleep disturbance at
3-6 weeks to 73% at 6 months. Most patients with selfreported BII showed normalized fatigue and anxiety levels
after explant by 3-6 weeks post-surgery which appeared
stable to 6 months. Between 20-25% of patients in Cohort
A did not improve. There was no statistically significant
difference in normalization of the PROMIS data between
the capsulectomy types. All patients in Cohort A showed
normalization toward mild to moderate in all 3 parameters
measured, however their scores were consistently higher
than the other 2 cohorts. (Figure 3)

Symptom Improvement
Cohort A (BII Cohort)
Ninety-four percent of the patients in Cohort A had at least
partial improvement in the number of symptoms reported
at baseline, with a reduction of 2-22 symptoms reported
at the 6 month follow up. Five patients had complete resolution of their symptoms, 2 of those patients had a total
capsulectomy and 2 had a partial capsulectomy and 1 had an
intact total capsulectomy. Three patients had no symptom
improvement at 6 months, all 3 had a total capsulectomy.
At 3-6 weeks patients in Cohort A had a 55% reduction
in the number of symptoms reported, at 6 months there
was a 68% reduction in the number of symptoms with 98%
follow-up. All reported baseline symptoms showed significant improvement at 3-6 weeks and further improvement
was seen at 6 months. Fatigue, brain fog, joint pain, and
muscle pain and weakness showed the greatest reduction
in reporting by Cohort A, fatigue decreased from 96% to
34% of subjects, brain fog from 90% to 22%, joint pain from
82% to 25%, and muscle pain and weakness from 80% to
22% of subjects. The type of capsulectomy, intact total,
total, or partial, showed similar symptom improvement with
no statistically significant difference in the reduction in the
number of symptoms based on the type of capsulectomy
performed.

Cohort B (Non-BII Cohort)
Thirty percent of Group B reported no symptoms at baseline,
which increased to 34% of subjects reporting no symptoms
at 6 months with 98% follow up. Group B had improvement
between baseline and 6 month follow up for headaches from
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implants were placed for primary augmentations and 25%
were placed for revision augmentation. Implants were
placed between 1990-2016 with a mean of 13.5 years.
Seventy-five percent of implants were intact, 25% were
ruptured silicone gel. Capsules described as Grade 1
in 43%, Grade 2 in 20%, Grade 3 in 20%, Grade 4 in 8%.
Thirty-eight percent of capsules were described as thin
and transparent, 33% thin and opaque, 22% thick and
opaque, and 8% thick and calcified. There was no statistically significant difference in the number of years implanted,
type of implant, presence of rupture or gel bleed between
the cohorts.
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Figure 3. PROMIS Score Change Over Time. (A) PROMIS
score demonstrates change over time for Anxiety at Baseline
(1), 3-6 weeks (2), and 6-months (3). (B) PROMIS score
demonstrates change over time for Fatigue at Baseline (1), 3-6
weeks (2), and 6-months (3). (C) PROMIS score demonstrates
change over time for Sleep Disturbance at Baseline (1), 3-6
weeks (2), and 6-months (3) Sleep disturbances.

26%-18% of patients reporting, heartburn reduced from 10%
to 4.5%, muscle pain and weakness 10%-4%, fatigue 26%15%, join pain 16%-9%, and insomnia 12%-4.5%. Group B patients did, however, report and increase in the percentage of
rashes from 4%-9%, and memory issues increased from 4% of
patients reporting at baseline to 7% at 6 months.

Cohort C (Control Cohort)
Fifty percent of subjects in Cohort C reported no systemic
symptoms at baseline, this number decreased to 44% of

There is extensive literature on a possible connection between breast implants and systemic symptoms or defined
connective tissue disease. Included in the existing literature are women with both saline and silicone implants and
studies that fail to apply any conventional diagnostic criteria.
Most studies lack identification of the type of implant, offer
unknown disease status prior to implantation, lack a consistent latent period or information on length of exposure,
provide inconsistent documentation of effects on symptoms after explantation, and consistently lack long-term
follow-up.20 The difficulty in defining BII is that most selfreported signs and symptoms are commonly found in the
general population.21 The constellation of symptoms that
characterize BII are also found in multiple other illnesses,
such as chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. In this study, data from both
a self-reported systemic symptoms questionnaire and
validated NIH PROMIS questionnaire were collected before and after surgery at defined post-operative intervals
to provide valid and reliable Patient Reported Outcomes
Measures (PROM) of health concepts relevant to clinicians
and researchers.22
This part 1 of the ASERF Systemic Symptoms in Women
Biospecimen Analysis Study focuses on the impact of
capsulectomy type and systemic symptom improvement.
This study enrolled 150 patients and followed strict inclusion and exclusion criteria. Data was prospectively
collected from sequential patients at 5 investigator sites
within the United States. Follow-up was robust, with
98%-100% follow-up at 3-6 weeks for all 3 cohorts, 78%98% at 6-months, and 1 year data is currently at 80%.
The baseline symptom surveys showed a statistically
significant difference in self-reported symptoms between Cohort A and the 2 control cohorts B and C. There
was no statistically significant difference in symptoms
between Cohort B and C consistent with the findings
of Misere, et al suggesting a potential bias among selfdesignated breast implant illness patients.23 This study
demonstrated at least partial symptom improvement in
96% of patients in Cohort A, with no specific constellation of symptoms or history that predicted this improvement except for self-reporting BII and undergoing an
explantation. The type of capsulectomy was recorded
by the surgeon and further documented by photography.
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subjects reporting no symptoms. At the 6 month follow up
visit cohort C reported a decrease in headaches from 20%
of subjects to 14%, dry eyes 12%-9%, and fatigue 10%-6%
with 78% follow-up. However, Cohort C self-reported an increase in anxiety from 18% of subjects to 23%, hair loss
2%-9%, and memory issues 8%-12%, brain fog 4%-11%, and
insomnia 4%-11%. (Figure 4)
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Figure 4. (A-C) Comparison of symptom resolution between the cohorts at 3-6 weeks and 6 months.

The results demonstrated that intact total, total, or partial capsulectomies all showed similar symptom improvement with no statistical difference in the reduction of
symptoms based on the type of capsulectomy (Appendix
D, available online at www.aestheticsurgeryjournal.com).
There was also no difference in the dose response based
on the number of years implanted as the average and
mean number of years implanted did not vary between
the cohorts. There was a statistically significant difference between implant shell surface and fill with more
smooth saline implants identified in Cohort A. There was
no statistical significance in the presence gel rupture or
bleed between the cohorts.
The limitations of this study include the relatively small
cohort size which was in part based on the expense of
the biospecimen analysis. These analyses should be considered exploratory as many comparisons were made and

it is expected that some results are statistically significant
due to chance alone. However, the size of each cohort was
determined to be large enough to provide statistical significance to the symptoms data collected. Further, there
are inherent limitations to patient reported symptoms
and medical histories. All patients had at least a partial
capsulectomy as capsules were sent for study analysis on
all subjects in the implant cohorts.
In addition to the qualitative systemic symptom data analyzed in this study, biospecimen data was collected from
all cohorts. This included the analysis of capsule tissue for
the presence of twenty-two heavy metals, microbes within
the capsule and on the implant surface, the evaluation of
patient’s blood for the presence of any antibodies to microbial toxin/superantigens and elevated serum cytokine
levels, and possible alternate causations such as vitamin
D deficiency or thyroid disease. Data was also collected to
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document potential sources of elevated heavy metals such
tattoos or diet. This data will be published in Part 2 and 3
of the ASERF study.

This study demonstrated at least partial symptom improvement in patients with self-reported systemic symptoms
following removal of their implants. After excluding other
potential causes for their symptoms, implant removal can
be discussed with patients who believe that their implants
are responsible for their symptoms. The data indicates that
women who self-report BII and have elevated anxiety and
experience improvement in their anxiety after explantation
which is sustained at least to 6 months. The data, however,
does not support the requirement for performing “en bloc”
removal of the breast implant and capsule in women selfreporting BII. Further, “en bloc” is a surgical procedure that
is indicated only for oncologic surgery. We report subjects
from Cohort A who had a complete symptom resolution
persisting through 6 months without a total capsulectomy,
demonstrating that symptom improvement is independent
of the presence of capsule remaining in the pocket. Total
intact capsulectomy, removing the entire implant and capsule together as 1 unit may require a longer incision and
carries higher risks than a total, partial, or no capsulectomy.
Patients considering implant removal for systemic symptoms that they attribute to their implants should weigh the
risks and benefits of explantation. Physicians and their patients should make informed decisions based on scientifically obtained data rather than the recommendations of
social media.

Supplemental Material
This article contains supplemental material located online at
www.aestheticsurgeryjournal.com.
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